The cost of managing HIV infection in highly treatment-experienced, HIV-infected adults in France

PharmacoEconomics

Volumn 28, Issue SUPPL. 1, 2010, Pages 59-68

  Colin, Xavier ^a   Lafuma, Antoine ^a   Costagliola, Dominique ^b   Lang, Jean Marie ^c   Guillon, Pascal ^d  

^a CEMKA EVAL   (France)

^b INSERM   (France)

^c UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^d Janssen Cilag   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONSULTATION; DRUG COST; FEMALE; FRANCE; HEALTH CARE COST; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITALIZATION COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; DRUG COSTS; FEMALE; FRANCE; HEALTH RESOURCES; HIV; HIV INFECTIONS; HUMANS; MALE; VIRAL LOAD;

EID: 78650737832     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11587450-000000000-00000     Document Type: Article

References (35)

1. Gazzard B, on behalf of the BHIVA Writing Committee. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008; 9: 563-608
2. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 Recommendations of the International AIDS Society - USA panel. JAMA 2010; 304: 321-33
3. Yéni P. Rapport du Groupe d'Experts 2010 sur la prise en charge médicale des patients infectées par le VIH, (version préliminaire) Recommandations du groupe d'expert. 2010. Available from URL: Http://www.sante-jeunesse-sports. gouv.fr/rapport-2010-sur-la-prise-en- charge-medicale-despersonnes- infectees-par-le-vih-sous-la-direction-du-pr-pa trick-yeni.html [Accessed 2010 Aug 25]
4. European AIDS Clinical Society (EACS). 2009 Guidelines for the Clinical Management and Treatment of HIV-infected adults in Europe; Version 5. November 2009 [online]. Available from URL: Http://www.europeanaidsclinicalso ciety.org/guidelinespdf/EACS-EuroGuidelines2009Full Version.pdf [Accessed 2010 Aug 25]
5. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-60
6. Walensky RP, Paltiel D, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 2006; 194: 11-19
7. Lane HC. Pathogenesis of HIV infection: Total CD4+ T-cell pool, immune activation, and inflammation. Top HIV Med 2010; 18: 2-6
8. Holkmann Olsen C, Gatell J, Ledergerber B, et al. Risk of AIDS and death at given HIV-RNA and CD4 cell counts, in relation to specific antiretroviral drugs in the regimen. AIDS 2005; 19: 319-30
9. Phillips AN, Lundgren JD. The CD4 lymphocyte count and risk of clinical progression: The T cell in HIV infection and disease. Curr Opin HIV AIDS 2006; 1: 43-9
10. Monforte A, Abrams D, Pradier C, et al., Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS 2008; 22: 2143-53
11. Gebo K, Fleishman J, Conviser R, et al. Contemporary costs of HIV healthcare in the HAART era [abstract 537]. 13th Conference on Retroviruses and Opportunistic Infections; 2006 Feb 5-8; Denver, USA
12. Chen RY, Accortt NA, Westfall AO, et al. Distribution of health care expenditures for HIV-infected patients. Clin Infect Dis 2006; 42: 1011-13
13. Levy A, Johnston K, Annemans L, et al. The impact of disease stage on direct medical costs of HIV management: A review of the international literature. PharmacoEconomics 2010; 28 Suppl. 1: 35-47
14. Ghatnekar O, Gisslen M, Hjortsberg C, et al. Medical resource use and cost of HIV-related care in the HAART era at a university clinic in Sweden [abstract P19.10/01]. 11th European AIDS Conference; 2007 Oct 24-27; Madrid, Spain
15. Caeckelbergh K, Moeremans K, Annemans L, et al. Cost of care for HIV/AIDS in Belgium according to disease stage [abstract P19.5/01]. 11th European AIDS Conference; 2007 Oct 24-27; Madrid, Spain
16. Flori YA, le Vaillant M. Use and cost of antiretrovirals in France 1995-2000: An analysis based on the Medical Dossier on Human Immunodeficiency (release 2) database. PharmacoEconomics 2004; 22: 1061-70
17. Hicks C, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatmentexperienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multidrug resistant patients with Tipranavir (RESIST) studies: An analysis of combined data from two randomised openlabel trials. Lancet 2006; 368: 466-75
18. Food and Drug Administration (FDA): Press Release: FDA approves darunavir; 2006 Jun 23 [online]. Available from URL: Www.fda.gov/NewsEvents/ Newsroom/PressAnnounce ments/2006/ucm108676.htm [Accessed 2010 Aug 25]
19. European Commission Community register of medicinal products for human use. PREZISTA; [online]. Available from URL: Http://ec.europa.eu/enterprise/ sectors/pharma ceuticals/documents/community-register/html/h380.htm [Accessed 2010 Aug 25]
20. Clotet B, Bellos N, Molina J, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: A pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369: 1169-78
21. Food and Drug Administration (FDA) Press Release. FDA approves novel antiretroviral drug; 2007 Aug 6 [online]. Available from URL: Http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108960.htm [Accessed 2010 Aug 25]
22. Food and Drug Administration (FDA) Press Release. FDA approves new antiretroviral drug; 2007 Oct 16 [online]. Available from URL: Http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm109008.htm [Accessed 2010 Aug 25]
23. Committee for Medicinal Products for Human Use (CHMP); 2007 [online]. Available from URL: Http://www.emea.eur opa.eu/htms/general/contacts/CHMP/CHMP. html [Accessed 2010 Aug 25]
24. Madruga JV, Cahn P, Grinsztejn B. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1- infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370: 29-38
25. Lazzarin A, Campbell T, Clotet B. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1- infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370: 39-48
26. GERS: Groupement pour l'Élaboration et la Réalisation de Statistiques. Nos missions; [online]. Available from URL: Http://www.gie-gers. fr/groupement/qui-sommes-nous.php3 [Accessed 2010 Aug 25]
27. Banque Claude Bernard Data base Groupe CEGEDIM, Boulogne Billancourt France; [online]. Available from URL: Http://www.resip.fr [Accessed 2010 Aug 25]
28. Base de données Hospitalière Française sur l'infection à VIH - ANRS CO4 FHDH. Inserm transfert SA, Paris, France, 2007.
29. ATIH: Agence Technique de l'information sur l'Hospitalisation. PSMI database; [online]. Available from URL: Http://www.atih.sante.fr/[Accessed 2010 Aug 25]
30. World Health Organization. International Classification of Diseases (ICD); [online]. Available from URL: Http://www.who.int/classifications/icd/en/ [Accessed 2010 Aug 25]
31. Circulaire DHOS/F3/F1 no 2005-103 du 23 février 2005 relative à la campagne tarifaire 2005 pour les activités de médecine, chirurgie, obstétrique et odontologie exercées dans les établissements de santé privés mentionné s aux d) et e) de l'article L. 162-22-6 du code de la sécurité sociale; [online]. Available from URL: Http://www.sante.gouv.fr/adm/dagpb/bo/ 2005/05-04/somchrono.htm [Accessed 2010 Aug 25]
32. Vallier N, Weill A, Salanave B, et al. Coût des trente affections de longue durée pour les béné ficiaires du régime géné ral de l'assurance maladie en 2004. Prat Organ Soins 2006; 37: 267-83
33. Detournay B, Voinet C, Bez J, et al. Consommation mé dicale des patients infecté s par le VIH suivis à l'Hôpital Purpan (Toulouse). Journal d'Economie Médicale 2003; 21: 367-76
34. Weill A, Chinaud F, Vallier N, et al. Fréquence et coûts des trente affections de longue durée de la région Midi- Pyréné es, année 2003. Rev Med Ass Maladie 2005; 36: 273-87
35. Ledergerber B, Lundgren JD, Walker AS, et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 2004; 364: 51-62